Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tenofovir + emtricitabine + zidovudine + abacavir
- Development stage
- Phase 4
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
This is a combination of four antiretroviral medications used in HIV treatment. The combination includes: - **Tenofovir disoproxil fumarate (TDF)**: A nucleotide reverse transcriptase inhibitor (NtRTI) - **Emtricitabine (FTC)**: A nucleoside reverse transcriptase inhibitor (NRTI) - **Zidovudine (ZDV)**: A nucleoside reverse transcriptase inhibitor (NRTI) - **Abacavir (ABC)**: A nucleoside reverse transcriptase inhibitor (NRTI) These medications work by inhibiting HIV reverse transcriptase, preventing viral replication. Each component has distinct adverse effect profiles: tenofovir primarily affects renal function and bone density, zidovudine causes hematological effects and lipoatrophy, abacavir can cause hypersensitivity reactions and potential cardiovascular effects, while emtricitabine has a relatively favorable safety profile.
02
Targets
Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on tenofovir + emtricitabine + zidovudine + abacavir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tenofovir + emtricitabine + zidovudine + abacavir.